EV Biologics Corp., a Wyoming-based biotechnology company, has engaged Foley to facilitate the propriety development of its exosome technology and technical innovation.
In its announcement, the company cited Foley’s standing at the top of intellectual property law in biotechnology and organics and its specialty in stem cell and extracellular vesicle technology.
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer.
Related News
12 May 2025
Press Releases
Foley Expands East Coast Litigation Bench, Adds Three Partners in New York and Raleigh
Foley & Lardner LLP announced today that it has strengthened its East Coast presence with the addition of three partners to its Litigation Department.
08 May 2025
Press Releases
Foley Expands Technology and Energy Capabilities with Addition of Two Digital Infrastructure Partners
Foley & Lardner LLP announced today the addition of partners Daniel Farris and Joe McClendon to its Chicago office, further enhancing the firm’s Technology Transactions, Cybersecurity, and Privacy Practice and its Energy & Infrastructure and Innovative Technology Sectors.
05 May 2025
Press Releases
American Telemedicine Association Elects Nathaniel Lacktman as Board of Directors Chair
Foley & Lardner LLP is pleased to announce that partner Nathaniel (Nate) Lacktman was elected as the new chair of the American Telemedicine Association (ATA) Board of Directors, effective immediately.